MURAL ONCOLOGY PLC (MURA) Stock Income Statement
USA - NASDAQ:MURA - IE000LK2BOB4 - Common Stock
2.1 USD
0 (0%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 135.69M | 138.26M | 196.24M | 184.92M | 175.37M | |||
| Research and Development | 106.96M | 110.67M | 165.53M | 167.19M | 159.82M | |||
| Selling, General, and Administrative Expenses | 28.74M | 27.60M | 30.71M | 17.73M | 15.55M | |||
| Operating Income | -135.69M | -138.26M | -196.24M | -184.92M | -175.37M | |||
| Interest Income/Expense | null | null | null | null | null | |||
| Other Income/Expense | 6.03M | 9.75M | 951.00K | null | null | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | -147.15M | -128.51M | -195.29M | -184.92M | -175.37M | |||
| Income Tax | 0 | 0 | 12.16M | 4.88M | 70.00K | |||
| Net Income | -147.15M | -128.51M | -207.45M | -189.81M | -175.43M | |||
| EBITDA | -131.93M | -134.75M | -193.67M | -183.42M | -173.87M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -8.5811 | -7.5799 | -12.4296 | -11.37 | -10.51 | |||
| Non GAAP EPS | -7.569999999999999 | -7.58 | null | null | null | |||
| Statistics | ||||||||
All data in USD